AstraZeneca Sues Actavis Over Planned Generic Vimovo

Law360, New York (May 13, 2013, 8:33 PM EDT) -- AstraZeneca AB sued Actavis Inc. in New Jersey federal court Friday to block the generic-drug maker from selling a version of the arthritis drug Vimovo.

The suit claims that Actavis' abbreviated new drug application, which it notified AstraZeneca of in March, infringes five patents covering the drug that expire between 2014 and 2023.

AstraZeneca claims that the infringement was willful and seeks a permanent injunction barring Actavis from infringing the patents.

It also asks the court to rule that the earliest date the generic version can...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.